TrialJAMA dermatology2020

Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial.

Emma Guttman-Yassky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.